Evaluation of the efficacy and safety of cellular bone allograft for ankle arthrodesis
10.3969/j.issn.1005-6483.2017.04.017
- VernacularTitle:骨细胞同种异体移植物用于踝关节融合术后疗效评估
- Author:
Jianhua LIU
- Keywords:
cellular bone allograft;
ankle fusion;
nonunion;
traumatic arthritis
- From:
Journal of Clinical Surgery
2017;25(4):292-294
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of cellular bone allograft(CBA)in ankle arthrodesis.Methods The clinical data of 56 patients with traumatic ankle joint injury and ankle joint injury treated in our hospital from April 2013 to April 2016 were retrospectively analyzed.Imaging was performed at 3 months after surgery,and the visual analogue(VAS)score of the patients,the ankle and foot surgery score(AOFAS),and the SF-36 health status questionnaire score were recorded.The group included 33 patients who were treated with CBA,and patients with simple fusion in the treatment group(n=23).Results 2 months after operation,the fusion rate of CBA group was 87.9% and the fusion rate of without CBA group was 52.2%.3 months after operation,the fusion rate of CBA group was not higher than that of group CBA,and the fusion rate was in group.The data showed a significant improvement in pain,function,and quality of life.No adverse events caused by CBA were observed during the study.Conclusion The rate of fusion was higher in patients treated with bone allograft(CBA)than in patients with autologous bone graft,and the fusion rate was not affected by high risk factors.CBA is a safe and effective graft material for the bone healing of damaged joints,which can provide an effective bone graft substitute for ankle arthrodesis.